Stryker Corporation (SYK) Stock Analysis — Probabli.AI
AI-powered analysis for SYK (Stryker Corporation): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
← Healthcare Stocks
Last price: $311.75 · Market cap: $119.2B · AI outlook: Bullish
Stryker Corporation (SYK) represents a blue-chip medtech compounder that has temporarily pulled back following a modest Q3 revenue estimate miss, creating a favorable risk-reward entry point. Wall Street consensus remains solidly bullish with a median price target of $370, implying ~18.7% near-term upside. Stryker's strategic moat is anchored by its Mako robotic ecosystem, which continues to…
Probabilistic 1-Year Outlook
- Bull 60% · Neutral 25% · Bear 15%
- 1-year price estimates — P10: $265 / P50: $365 / P90: $425
- Analyst consensus is firmly in BUY territory with 30 analysts pointing to a median target of $370 (+18.7% upside). While a recent Q3 top-line miss has introduced minor near-term volatility, double-digit procedural…
5-Year Outlook
- Bull 65% · Neutral 22% · Bear 13%
- 5-year price estimates — P10: $340 / P50: $560 / P90: $740
SWOT Highlights
- Strength: Market leadership in orthopedic reconstruction, surgical equipment, and neurotechnology
- Strength: Mako robotic-arm assisted surgical platform creates significant hospital lock-in and high-margin recurring consumables revenue
- Risk: Periodic vulnerability to hospital capital expenditure budgeting cycles
- Risk: Exposure to hospital staffing shortages and supply chain bottlenecks for microelectronics
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
30 Wall Street analysts rate SYK a BUY with a mean price target of $364.83. Stryker Corporation currently pays a dividend with a yield of approximately 1.13%.
Last analyzed · Model: gemini-3.8-flash. How this forecast works · Accuracy & validation.
SYK forecast details · SYK sentiment details
Recent saved forecast research
AI-generated research records, not evaluated investment results.
- Stryker Corporation (SYK) — saved
Stryker Corporation (SYK) represents a blue-chip medtech compounder that has temporarily pulled back following a modest Q3 revenue estimate miss, creating a favorable risk-reward entry point. Wall Street consensus remains solidly bullish wi
- Stryker Corporation (SYK) — saved
Stryker Corporation is well-positioned for future growth driven by its innovative product offerings in the medical devices space, consistent earnings outperformance, and favorable analyst sentiment. While there are risks like supply chain i
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.